DENVER--(BUSINESS WIRE)--MusclePharm® Corporation (OTCBB:MSLP - News), a fast-growing nutritional supplement company with a proprietary formulation used in eight performance products, announced today that the former Assistant Surgeon General Dr. Roscoe M. Moore, Jr. joins MusclePharm as its Chief Scientific Director.
“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining our Company as Chief Scientific Director. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to MusclePharm. In addition to overseeing our next generation of product offerings, he will assist in our path towards insurance reimbursement for our Re-Con product for HIV patients suffering from involuntary weight loss and catabolic cachexia, which is a very large market,” commented Cory Gregory, President of MusclePharm. “Dr. Moore’s decision to join MusclePharm is a reinforcement of the quality and effectiveness of our products and our strong research and developments efforts.”
MusclePharm presented at the XVIII International Aids Conference in Vienna, Austria sponsored by NAPWA and The AIDS Institute on Thursday, July 22, 2010 on the use of Re-Con, which was enthusiastically received by an audience of 200+ people including several leading clinicians and researchers and top government representatives. The Company presented evidence that its product, Re-Con, has shown clinical attributes that dramatically addresses the involuntary weight loss and catabolic cachexia in HIV patients on HAART (highly active antiretroviral therapy).
Dr. Roscoe M. Moore, Jr. commented, ““Unintentional and involuntary weight loss in people living with HIV/AIDS have long been recognized as a serious consequence of this disease. The nutritional requirements among persons undergoing antiretroviral therapy have not been adequately and systematically addressed. Therapeutic nutritional supplementation products, like those provided by MusclePharm, are essential in maintaining the health status of HIV/AIDS patients. I look forward to joining MusclePharm in order to provide the most effective evidence-based approach to assure appropriate and adequate therapeutic nutritional supplementation to mitigate the impact and progression of wasting syndrome in HIV/AIDS patients."
New York and other state Medicaid programs, as well as AIDS drug assistance programs and nation-wide Veterans Administration therapeutic formularies all recognize the value of therapeutic nutritional supplementation interventions for the treatment of catabolic cachexia, the prognostic markers of which are associated with loss of appetite, uncontrolled diarrhea, macro and micronutrient deficiencies, abnormal cytokine presentation, proinflammatory oxidative stress and decreased caloric intake.
Several reports of observed clinical improvement in U.S. AIDS patients in outpatient settings indicate that Re-Con in conjunction with Medicaid approved sources of whey protein and HMB intake have dramatically increased lean body mass in patients diagnosed with catabolic cachexia, with definitive correlations to the prevention of the onset of HIV drug resistance. Clinical studies to further examine this phenomenon are now being planned by leading clinicians and community advocates in multi-site trials across the U.S. and Europe. A proposal for the federal facilitation of these studies is being prepared for the Adult AIDS Clinical Trials Group at the National Institute of Allergy and Infectious and Diseases, National Institutes of Health.